We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Elevated Blood Sugar a Cardiovascular Disease Risk Not Linked to Cholesterol Levels

By LabMedica International staff writers
Posted on 21 Sep 2014
Individuals with prediabetes and diabetes are at high risk for cardiovascular events such as myocardial infarction that can be predicted by elevated levels of troponin T.

The protein troponin T binds to tropomyosin and helps position it on actin, and with the rest of the troponin complex modulates contraction of striated muscle. More...
In patients with stable coronary artery disease, troponin T concentrations have been found to be significantly associated with the incidence of cardiovascular death and heart failure.

In a recent study, investigators at Johns Hopkins University (Baltimore, MD, USA) reported that individuals with pre-diabetes or diabetes who displayed elevated levels of troponin T were approximately six times more likely to experience a cardiovascular incident than were those with normal blood sugar levels.

These findings were obtained by using a highly sensitive troponin T assay to determine levels of the protein in blood samples from more than 9,000 participants in the Atherosclerosis Risk in Communities Study (ARIC) at two time points. At the first measurement those with diabetes were two and a half times more likely to have elevated troponin levels than those without. At follow-up 14 years later, diabetics with elevated troponin were seen to be six times more likely to develop heart failure and four times more likely to have a heart attack.

Due to the link between cardiovascular disease and diabetes, patients with newly diagnosed diabetes are typically prescribed a cholesterol-lowering statin. "However, this study suggests that there may be people with diabetes whose heart risk may have nothing to do with cholesterol," said first author Dr. Elizabeth Selvin, associate professor of epidemiology at Johns Hopkins University. "Statin treatment may not be sufficient to prevent damage to the heart in people with diabetes. Even though there may be no symptoms yet, our research suggests there is microvascular damage being done to the heart which is leading to heart failure and even death. It puts what we know about heart damage in diabetes on its head. It looks like diabetes may be slowly killing heart muscle in ways we had not thought of before."

The study was published in the August 2014 online edition of the journal Circulation.

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.